Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 12, 2003, Pages 1364-1372

  Suzuki, Seiji ^a,b   Kondo, Yutaka ^b   Hirashima, Noboru ^a   Kato, Hideaki ^b   Sugauchi, Fuminaka ^a,b   Tanaka, Yasuhito ^a   Orito, Etsuro ^b   Yang, Ying ^c   Shen, Yu ^c   Sakakibara, Kenji ^a   Ueda, Ryuzo ^b   Mizokami, Masashi ^a,b  

^a CHUKYO HOSPITAL   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Genetic instability; Microdissection; Microsatellite markers; Predictor; Tumor suppressor gene

Indexed keywords

INTERFERON;

ADULT; ARTICLE; CANCER TISSUE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE FREQUENCY; HEPATITIS C; HEPATITIS C VIRUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MEDICAL ASSESSMENT; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; PREDICTION; PRIORITY JOURNAL; STAGING; TREATMENT OUTCOME;

EID: 9144229619     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.03222.x     Document Type: Article

References (32)

1. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 942-1956.
2. Colombo M, Kuo G, Choo QL et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2: 1006-8.
3. Bruix J, Barrera JM, Calvet X et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-6.
4. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 1986; 315: 1575-8.
5. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1989; 321: 1501-6.
6. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 1989; 321: 1506-10.
7. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1990; 323: 295-301.
8. Di Bisceglie AM, Fong TL, Fried MW et al. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am. J. Gastroenterol. 1993; 88: 1887-92.
9. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
10. Hirashima N, Mizokami M, Orito E et al. Case report: Development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha. J. Gastroenterol. Hepatol. 1996; 11: 955-8.
11. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-402.
12. Toyoda H, Kumada T, Honda T et al. Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C. J. Gastroenterol Hepatol 2001; 16: 1131-7.
13. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997; 386: 623-7.
14. Macdonald GA, Greenson JK, Saito K, Cherian SP, Appelman HD, Boland CR. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology 1998; 28: 90-7.
15. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Microsatellite instability associated with hepatocarcinogenesis. J. Hepatol 1999; 31: 529-36.
16. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis - A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000; 32: 970-9.
17. Shintani Y, Yotsuyanagi H, Moriya K et al. The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C. Cancer 2000; 88: 2478-86.
18. Sambrook J, Fritsch EF, Maniatis T. Chapter 7. Molecular Cloning: a Laboratory Manual. New York: Cold Spring Harbor Laboratory, 1989; 9.16-9.23.
19. Weissenbach J, Gyapay G, Dib C et al. A second-generation linkage map of the human genome. Nature 1992; 359: 794-801.
20. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997; 14: 2927-33.
21. Roncalli M, Bianchi P, Grimaldi GC et al. Fractional allelic loss in non-end-stage cirrhosis: correlations with hepatocellular carcinoma development during follow-up. Hepatology 2000; 31: 846-50.
22. Kuroki T, Fujiwara Y, Tsuchiya E et al. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: loss of heterozygosity of chromosome arm1p occurs at an early stage of hepatocarcinogenesis. Genes Chromosomes Cancer 1995; 13: 163-7.
23. Konishi M, Kikuchi-Yanoshita R, Tanaka K et al. Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn. J. Cancer Res. 1993; 84: 893-9.
24. Niketeghad F, Decker HJ, Caselmann WH et al. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br. J. Cancer 2001; 85: 697-704.
25. Yeh SH, Chen PJ, Shau WY et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 2001; 121: 699-709.
26. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995; 10: 1725-9.
27. Kishimoto Y, Shiota G, Wada K et al. Frequent loss in chromosome 8p loci in liver cirrhosis accompanying hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 1996; 122: 585-9.
28. Inazawa J, Ariyama T, Abe T et al. PTPN13, a Fas-associated protein tyrosine phosphatase, is located on the long arm of chromosome 4 at band q21.3. Genomics 1996; 31: 240-2.
29. Knuutila S, Aalto Y, Autio K et al. DNA copy number losses inhuman neoplasms. Am. J. Pathol. 1999; 155: 683-94.
30. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 1998; 58: 2196-9.
31. Kusano N, Shiraishi K, Kubo K, Oga A, Okita K, Sasaki K. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 1999; 29: 1858-62.
32. Wong N, Lai P, Lee SW et al. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am. J. Pathol. 1999; 154: 37-43.